AOD-9604

AOD-9604 is a modified peptide fragment derived from the C-terminal region of human growth hormone, isolating the segment believed to be responsible for GH's effects on fat metabolism. Unlike full-length growth hormone, AOD-9604 is designed to avoid significant impact on growth-related (IGF-1) or blood sugar pathways. The peptide is thought to interact with beta-3 adrenergic receptors on fat cells, stimulating lipolysis (the breakdown of stored fat) and inhibiting lipogenesis (the formation of new fat). EdgeRx offers AOD-9604 through a clinician-supervised peptide protocol, prescribed by licensed physicians for eligible patients as part of an individualized metabolic health plan.